Back to search

Article

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

2022-04-20

Abstract excerpt

Antibody-drug conjugates (ADCs) are promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We present a comprehensive therapeutic and biomarker analysi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2fc73a87-2e79-5cec-84f9-58e8f2c7301b
DOI
10.1101/2022.04.19.488784
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancerDOI 10.1101/2022.04.19.488784
Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerSemantic proximity
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancerSemantic proximity
Integrative molecular analyses define the genomic, transcriptomic, and epigenomic correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancerSemantic proximity
ITC-6102RO, A Novel B7-H3 Antibody-Drug Conjugate, Exhibits Potent Therapeutic Effects against B7-H3 Expressing Solid TumorsSemantic proximity
CD276 (B7-H3) as a Companion Diagnostic Biomarker for Glioblastoma: Multi-Platform Validation and Therapeutic ImplicationsSemantic proximity
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity
Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.Semantic proximity
Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory PropertiesSemantic proximity
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancerSemantic proximity
Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3Semantic proximity
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.Semantic proximity
Select a neighboring publication to make it the new centre.